Article

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer

2025-12-01

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> <italic>Epidermal growth factor receptor</italic> ( <italic>EGFR</italic> ) mutations represent one of the most frequent oncogenic driver in non-small cell lung cancer (NSCLC). Amivantamab, a bispecific antibody targeting EGFR and MNNG HOS Transforming (MET), has demonstrated clinical benefit in <italic>EGFR</italic> -mutant NSCLC through dual blockade,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: adee8f53-04c4-5a63-a4e5-88a589dc4a9d
DOI: 10.21203/rs.3.rs-8141506/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancerDOI 10.21203/rs.3.rs-8141506/v1Read

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.Semantic proximity Read

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.Semantic proximity Read

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.Semantic proximity Read

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read

Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage TrogocytosisSemantic proximity Read

Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.Semantic proximity Read

<p>Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)</p>.Semantic proximity Read

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.Semantic proximity Read

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Semantic proximity Read

Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer.Semantic proximity Read

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.Semantic proximity Read

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.Semantic proximity Read